Vantive CONNECT Home Therapy Evidence

Compelling evidence for using automated peritoneal dialysis (APD) powered by Vantive CONNECT

Use of Vantive CONNECT Clinician (Sharesource Connectivity Platform) and Vantive CONNECT Success Therapy Services (PD Telecare) — has yielded growing evidence demonstrating improved patient outcomes1-3 and significant care-enhancing benefits for clinicians and health systems.4-6

Proven benefits

Vantive CONNECT Clinician and Therapy Services have has been associated with significant patient benefits — improved time on therapy,1,2 reduced complications, such as hospitalization,3 and the potential for improved survival.3 Clinicians and health systems gain more time to spend on patient care,4 lower resource utilization and costs,5 and greater visibility into patient adherence.6

Improved time on therapy1

3.2 months longer

(when compared to therapy without RPM)

See the evidence

Lower 90-day dropout rate2

46.9% lower

(with use of PD Telecare, compared to historical data)

See the evidence

Reduced complications3

69% lower incidence rate of hospitalizations due to fluid overload and/or insufficient dialysis efficiency

(when compared to PD therapy without RPM)

Potential for improved survival3

45% lower incidence rate of all-cause mortality

51% lower incidence rate of cardiovascular-specific mortality 

(when compared to PD therapy without RPM)

More time spent on proactive patient care4

32% increase in proactive activities

17% decrease in reactive activities

(in an evaluative study)

See the evidence

Lower resource utilization and costs5

1-2 fewer hospitalizations

1-4 fewer home visits

4-8 fewer unplanned clinic visits

2-5 fewer ER visits

~$23,000 cost savings for 12 patients in the study

(in a simulated environment)

See the evidence

Greater visibility into patient adherence6

Finding: 24% of patients missed treatment time in first week of therapy

Implication: Potential for early intervention

(when compared to PD therapy without RPM)

See the evidence

Important Safety Information

Intended Use
 

The Sharesource Connectivity Platform portal is intended for use by healthcare professionals to remotely communicate new or modified treatment parameters with compatible dialysis instruments and transfer completed treatment data to a central database to aid in the review, analysis, and evaluation of patients’ historical treatment results. This system is not intended to be a substitute for good clinical management practices, nor does its operation create decisions or treatment pathways.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

Vantive, PD Telecare and Sharesource are trademarks of Vantive Health LLC or its affiliates.

References

  1. Sanabria M, Vesga J, Lindholm B, et al. Time on therapy of automated peritoneal dialysis with and without remote patient monitoring: a cohort study. Int J Nephrol. 2022;Aug 2022:8646775.

  2. Todd L, Gellens M, Mooney A, Mancini A. Peritoneal dialysis supplemental telephone support program to reduce 90-day drop out. J Am Soc Nephrol. 2021;32:327-328. Abstract PO0967.

  3. Paniagua R, Ramos A, Ávila M, et al. Remote monitoring of automated peritoneal dialysis reduces mortality, adverse events and hospitalizations: a cluster-randomized controlled trial. Nephrol Dial Transplant. 2025;40(3):588-597.

  4. Wood E, McCarthy K, Roper M. Remote monitoring of peritoneal dialysis: Evaluating the impact of the Claria Sharesource system. J Kidney Care. 2019;4(1):16-24.

  5. Makhija D, Alscher MD, Becker S, et al. Remote monitoring of automated peritoneal dialysis patients: Assessing clinical and economic value. Telemed J E Health. 2018;24(4):315-323.

  6. Firanek C, Salas M, Gellens M, Gatesman RD, Wiebenson D, Sloand J. Discrepancy between prescribed and actual APD prescription delivery: Identification using cycler remote management technology. Neph Dial Trans. 2017;32(suppl 3):iii633.